ANI Pharmaceuticals (ANIP) stock price, revenue, and financials

ANI Pharmaceuticals market cap is $577.4 m, and annual revenue was $208.48 m in FY 2020

$577.4 M

ANIP Mkt cap, 12-Nov-2021

$54.5 M

ANI Pharmaceuticals Revenue Q1, 2021
ANI Pharmaceuticals Gross profit (Q1, 2021)34.5 M
ANI Pharmaceuticals Gross profit margin (Q1, 2021), %63.3%
ANI Pharmaceuticals Net income (Q1, 2021)86 K
ANI Pharmaceuticals EBIT (Q1, 2021)3 M
ANI Pharmaceuticals Cash, 31-Mar-202125.1 M
ANI Pharmaceuticals EV735.8 M
Get notified regarding key financial metrics and revenue changes at ANI PharmaceuticalsLearn more
Banner background

ANI Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

81.0k182.8k114.0k108.8k110.4k145.0k6.2m7.8m10.9m6.6m17.4m18.8m19.5m20.0m20.6m31.3m38.5m36.6m44.8m48.2m46.5m47.3m50.7m52.9m54.4m51.3m49.8m48.5m53.0m54.5m

Cost of goods sold

2.1m2.6m2.6m2.1m3.1m2.8m3.1m3.3m3.4m11.8m16.7m16.4m21.1m21.1m20.7m16.6m15.6m14.7m15.6m15.0m21.8m20.7m20.1m20.0m

Gross profit

4.1m5.2m8.3m4.5m14.3m16.0m16.4m16.7m17.1m19.5m21.9m20.2m23.6m27.1m25.8m30.7m35.1m38.2m38.7m36.3m28.0m27.8m32.9m34.5m

Gross profit Margin, %

66%66%76%68%82%85%84%84%83%62%57%55%53%56%55%65%69%72%71%71%56%57%62%63%

R&D expense

11.1m11.5m5.2m5.4m3.9m972.0k437.2k453.9k376.0k851.0k883.0k403.0k995.0k815.0k966.0k764.0k1.0m1.6m2.2m2.6m2.1m5.1m4.7m4.4m5.8m5.0m6.3m3.0m2.9m3.0m

General and administrative expense

2.0m1.7m1.8m1.9m1.5m1.9m1.5m1.8m3.7m5.4m4.1m4.8m5.6m5.4m5.9m7.6m6.9m7.3m7.4m8.0m9.0m10.0m11.8m13.3m14.2m14.4m13.7m21.2m15.7m17.6m

Operating expense total

13.1m13.2m7.0m7.3m5.4m2.9m7.8m4.4m4.8m7.0m6.1m6.5m8.0m11.5m11.5m14.3m13.9m15.6m16.6m17.8m19.3m23.4m25.0m33.8m29.4m29.0m35.8m39.1m30.1m31.5m

Depreciation and amortization

381.7k703.0k706.0k1.2m1.3m1.4m2.0m4.6m6.0m6.0m6.7m7.1m7.1m8.2m8.3m8.5m16.1m9.5m9.5m11.2m11.2m11.4m10.9m

EBIT

(3.8m)810.3k3.5m(2.5m)8.2m9.6m8.4m8.5m5.7m5.2m7.9m4.6m7.0m9.3m6.5m7.3m10.1m4.4m9.3m7.3m(7.8m)(11.3m)2.8m3.0m

EBIT margin, %

(61%)10%32%(37%)47%51%43%42%28%17%21%13%16%19%14%15%20%8%17%14%(16%)(23%)5%6%

Interest expense

172.0k172.0k124.2k92.0k67.1k64.7k374.5k3.0k10.0k2.7m2.7m2.8m2.8m2.9m2.9m3.0m3.1m3.6m3.7m3.8m3.4m3.4m3.3m2.0m2.4m2.5m2.5m

Interest income

13.0k2.0k2.0k1.4k1.9k1.9k

Investment income

1.7k1.5k

Pre tax profit

(6.2m)(4.6m)957.9k3.5m(2.5m)8.3m6.9m5.7m5.7m2.9m2.4m5.0m1.7m4.0m6.4m2.8m3.5m6.4m918.0k5.9m4.0m(9.9m)(13.8m)63.0k100.0k

Income tax expense

(121.8k)82.9k165.0k(133.0k)1.5m2.5m2.1m(1.1m)1.5m1.2m2.5m523.0k1.3m1.7m592.0k726.0k1.3m469.0k(653.0k)64.0k(2.9m)(1.4m)(371.0k)(10.0k)

Net Income

(15.0m)(12.7m)(10.3m)(7.3m)(6.1m)(2.3m)(4.6m)1.2m3.4m(2.4m)6.7m4.4m3.6m4.6m1.3m1.1m2.5m1.2m2.7m4.7m2.3m2.8m5.0m449.0k6.6m3.9m(7.0m)(12.3m)434.0k86.0k

ANI Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

37.1m69.6m49.5m42.4m38.0m29.4m12.6m10.9m51.4m53.0m35.1m165.6m166.7m150.9m77.7m15.0m16.2m10.8m8.4m18.0m52.0m55.0m44.1m38.2m40.6m59.7m20.4m27.7m17.9m25.1m

Accounts Receivable

6.4m9.5m10.9m7.8m14.6m17.4m18.9m21.6m22.5m35.6m47.5m46.7m55.5m62.2m54.8m56.1m67.6m67.4m76.3m70.7m82.4m73.2m83.7m91.9m

Prepaid Expenses

1.0m943.7k716.9k512.6k534.0k277.9k251.8k580.6k566.0k493.0k599.0k1.5m1.6m2.0m1.3m4.0m2.7m3.6m2.7m4.8m2.3m1.8m5.0m4.2m3.3m5.0m3.0m3.1m3.4m5.9m

Inventories

2.6m2.8m5.1m5.9m7.3m10.7m12.7m13.7m13.9m25.1m28.3m45.9m42.3m38.5m34.3m37.8m40.0m42.0m45.3m46.2m52.9m52.6m59.2m59.9m

Current Assets

38.1m70.5m50.2m42.9m38.6m31.9m24.1m26.1m67.9m67.2m57.6m203.0m208.9m197.5m116.6m79.8m95.5m107.0m112.9m125.6m143.4m152.4m156.8m151.8m168.9m182.4m158.7m156.5m165.8m182.8m

PP&E

1.1m855.0k884.3k862.4k1.2m4.7m4.6m4.5m4.6m5.0m5.3m5.2m5.8m8.4m8.9m9.7m12.9m15.0m17.4m21.9m22.8m37.4m38.4m39.0m39.8m40.4m39.9m40.4m40.8m

Goodwill

1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m1.8m4.2m3.6m3.6m3.6m3.6m3.6m3.6m3.6m

Total Assets

42.8m74.9m54.6m47.3m43.2m35.4m41.7m43.3m96.7m95.4m107.6m266.0m270.1m283.3m291.6m308.0m319.4m357.1m359.2m370.5m418.0m424.2m439.4m434.4m446.9m456.8m482.2m465.4m462.6m463.8m

Accounts Payable

6.3m6.0m3.3m3.8m2.0m164.4k1.6m2.1m2.7m1.7m3.1m2.3m1.3m2.6m3.0m5.0m4.7m4.8m3.2m5.8m4.9m7.9m7.3m10.5m9.8m11.0m12.5m14.2m13.5m13.8m

Short-term debt

100.0k1.2m3.8m5.2m5.7m117.4m4.1m4.2m11.9m12.3m12.8m14.4m

Current Liabilities

11.5m11.5m6.1m16.4m10.9m6.2m6.6m4.6m3.8m8.1m9.1m6.9m12.2m16.2m24.7m30.5m32.4m28.3m36.4m39.7m39.7m46.9m165.1m166.8m170.7m79.4m79.1m75.9m82.8m

Long-term debt

112.2m113.7m115.2m115.2m117.0m118.8m152.5m154.4m151.3m198.7m199.4m200.1m66.5m65.7m64.9m188.1m177.9m175.2m169.0m

Total Debt

100.0k1.2m112.2m113.7m115.2m115.2m117.0m118.8m30.0m154.4m151.3m202.5m204.6m205.8m183.9m69.8m69.0m200.0m190.2m187.9m183.4m

Total Liabilities

31.2m30.7m16.6m16.4m10.9m9.3m121.2m120.6m127.4m131.4m144.2m150.5m184.9m182.7m187.7m238.4m239.1m247.0m234.7m239.3m243.6m281.1m274.0m267.5m260.1m

Common Stock

209.4m254.7m265.5m265.8m273.3m273.3m1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k

Preferred Stock

Additional Paid-in Capital

89.0m89.0m137.3m139.1m140.2m160.1m161.4m163.1m165.7m168.2m170.7m174.0m175.9m177.4m181.6m184.5m186.5m190.0m194.9m197.5m203.5m209.4m211.8m216.2m

Retained Earnings

(197.9m)(210.6m)(227.5m)(234.8m)(241.0m)(247.2m)(53.1m)(51.9m)(45.1m)(47.5m)(40.7m)(15.4m)(11.8m)(7.2m)(5.5m)(4.4m)(1.8m)(1.8m)903.0k5.6m(1.8m)1.0m6.1m11.9m18.5m22.4m10.6m(1.8m)(1.3m)(4.9m)

Total Equity

11.5m44.1m38.0m30.9m32.3m26.0m35.5m36.7m92.1m91.6m99.5m144.7m149.5m155.9m160.2m163.8m168.8m172.2m176.5m182.8m179.6m185.1m192.5m199.7m207.7m213.1m201.2m191.3m195.1m203.7m

Debt to Equity Ratio

0 x0 x0.8 x0.8 x0.7 x0.7 x0.7 x0.7 x0.2 x0.9 x0.8 x1.1 x1.1 x1.1 x0.9 x0.3 x

Debt to Assets Ratio

0 x0 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.1 x0.4 x0.4 x0.5 x0.5 x0.5 x0.4 x0.2 x

Financial Leverage

3.7 x1.7 x1.4 x1.5 x1.3 x1.4 x1.2 x1.2 x1 x1 x1.1 x1.8 x1.8 x1.8 x1.8 x1.9 x1.9 x2.1 x2 x2 x2.3 x2.3 x2.3 x2.2 x2.2 x2.1 x2.4 x2.4 x2.4 x2.3 x

ANI Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(32.2m)(45.0m)(10.3m)(17.6m)(23.7m)(2.3m)(4.3m)3.4m996.0k7.7m4.4m7.9m12.5m1.3m2.5m5.0m1.2m3.8m8.6m2.3m5.0m10.1m449.0k7.0m10.9m(7.0m)(19.3m)(18.9m)86.0k

Depreciation and Amortization

82.5k118.1k30.9k61.8k87.5k166.4k291.1k672.8k703.0k1.4m2.6m1.3m2.7m4.8m4.6m10.6m16.5m6.7m13.8m20.9m8.2m16.5m25.1m17.2m25.6m35.0m11.2m22.4m33.7m10.9m

Accounts Receivable

(995.1k)(4.1m)1.6m4.7m(2.1m)(74.0k)(1.6m)(4.3m)(549.0k)(13.6m)(25.5m)(802.0k)(9.6m)(16.3m)4.0m2.7m(7.5m)(2.6m)(11.4m)(5.9m)(10.2m)(1.0m)(11.6m)3.9m

Inventories

225.0k525.0(1.6m)(2.4m)(3.3m)(3.2m)(5.2m)(6.2m)(535.0k)(807.0k)(4.0m)(2.8m)776.0k4.6m3.4m171.0k118.0k(1.5m)(4.8m)(5.7m)3.7m4.1m(1.2m)876.0k

Accounts Payable

3.2m3.0m(1.1m)(1.3m)(3.8m)(1.6m)(358.8k)93.3k1.2m302.0k630.0k(471.0k)(1.4m)(130.0k)889.0k2.9m2.6m1.3m(345.0k)2.1m1.7m4.6m2.3m2.0m1.3m2.1m(1.3m)665.0k(146.0k)2.5m

Cash From Operating Activities

(24.4m)(36.9m)(7.7m)(14.7m)(22.1m)(4.1m)(988.0k)(2.6m)5.2m7.1m11.3m1.1m2.3m12.6m11.0m14.3m15.4m6.5m6.5m23.6m22.9m31.5m39.8m14.3m19.0m40.8m1.7m22.6m21.0m20.7m

Purchases of PP&E

(542.9k)(645.6k)(54.2k)(63.3k)(528.7k)(127.7k)(161.4k)(118.0k)(371.0k)(782.0k)(112.0k)(310.0k)(1.1m)(1.4m)(2.1m)(3.2m)(2.1m)(4.4m)(6.9m)(2.3m)(3.4m)(4.7m)(1.8m)(3.4m)(4.9m)(1.5m)(2.3m)(4.0m)(698.0k)

Cash From Investing Activities

(542.9k)(645.6k)(62.2k)(71.3k)(536.7k)(1.3m)18.1m18.0m(12.6m)(12.9m)(35.4m)(4.6m)(4.8m)(31.6m)(85.6m)(151.6m)(152.7m)(53.1m)(55.4m)(57.9m)(2.3m)(8.5m)(27.0m)(20.3m)(24.2m)(26.2m)(57.5m)(60.4m)(66.2m)(737.0k)

Short-term Borrowings

4.1m(7.5m)(7.5m)

Cash From Financing Activities

23.9m69.0m(658.0)3.5m(4.5m)(4.5m)47.7m47.6m48.1m18.0k178.0k892.0k(2.4m)(2.4m)(1.2m)30.0m29.9m24.9m170.0k861.0k130.0k1.2m2.8m2.0m13.9m3.1m769.0k(2.7m)

Net Change in Cash

(1.0m)31.4m(7.8m)(14.8m)(19.2m)(5.4m)12.6m10.9m40.3m41.9m23.9m(3.5m)(2.3m)(18.1m)(76.9m)(139.7m)(138.5m)(16.5m)(19.0m)(9.3m)20.8m23.9m13.0m(4.8m)(2.4m)16.7m(41.9m)(34.7m)(44.5m)17.2m

Interest Paid

344.0k344.0k184.1k184.1k249.6k249.6k(3.0k)2.0m2.0m2.2m2.2m2.1m2.2m453.0k3.2m3.8m449.0k2.9m3.6m1.8m3.5m5.1m2.0m

Income Taxes Paid

60.0k60.0k137.0k6.0m9.5m10.7m1.6m2.2m5.8m4.0k9.9m12.5m2.9m3.9m8.7m9.9m95.0k523.0k4.9m112.0k

ANI Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

3.7 x

ANI Pharmaceuticals Employee Rating

3.711 votes
Culture & Values
3
Work/Life Balance
4
Senior Management
3.3
Salary & Benefits
2.8
Career Opportunities
3.3
Source